Zhi Peng

机构：Nanjing University of Chinese Medicine, Peking University, Peking University Cancer Hospital, Ministry of Education · ORCID：0000-0003-4063-9813

发表论文 161 篇 · 总被引 4677 次 · h-index 35

代表论文

• Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results (2024 · Nature Medicine · 被引 194)
• Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial (2025 · The Lancet · 被引 128)
• A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial (2025 · Nature Medicine · 被引 19)
• Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2 -Positive Locally Advanced Resectable Gastric Cancer (2025 · JAMA Oncology · 被引 19)
• Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study (2025 · Signal Transduction and Targeted Therapy · 被引 16)
• Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers (2024 · Cancer Immunology Immunotherapy · 被引 16)